Sensitivity of hepatocellular carcinoma to nine anticancer drugs is unchanged after administration of epirubicin suspended in lipiodol.
Multidrug resistance is a major obstacle to the successful chemotherapy for human cancers. The chemosensitivities of hepatocellular carcinoma (HCC) treated with preoperative lipiodolization (LPD) to anticancer agents were compared to those without chemotherapy. Data on 22 patients with HCC treated with LPD (epirubicin, 20-70 mg/m(2) and lipiodol, 0.05-0.25 ml/kg) prior to hepatectomy (LPD group) and 77 with HCC treated by hepatic resection alone (control group) were compared. Chemosensitivities of resected tissues were tested by succinate dehydrogenase inhibition (SDI) tests for nine anticancer agents, epirubicin, adriamycin, mitomycin-C, cisplatin, carboquone, cyclophosphamide, 5-fluorouracil, etoposide, and vindesine. Among the anticancer agents studied, HCC was most sensitive (38% in the LPD group, 50% in the control) to cyclophosphamide and least sensitive (0% in LPD group, 2% in the control) to etoposide. There was no statistically significant difference in chemosensitivity between the two groups. As HCC does not seem to acquire multidrug resistance after single LPD with epirubicin, repeated LPD with epirubicin can be considered.